Advertisement

Topics

Zogenix’s ZX008 Demonstrates Positive Results in Late-Stage Dravet Syndrome Study

16:38 EDT 12 Jul 2018 | Speciality Pharma Journal

EMERYVILLE, Calif., July 12, 2018 (GLOBE NEWSWIRE) —  Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of children and young …

Original Article: Zogenix’s ZX008 Demonstrates Positive Results in Late-Stage Dravet Syndrome Study

NEXT ARTICLE

More From BioPortfolio on "Zogenix’s ZX008 Demonstrates Positive Results in Late-Stage Dravet Syndrome Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...